Please assess the completion status of the following clinical trial:

Trial Title: APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females with pathologically determined locally advanced or metastatic human epidermal growth factor receptor 2 positive (HER2/neu+) breast cancer~* Have progressed after treatment with chemotherapy including a taxane and trastuzumab~* Must have measurable disease by RECIST~* ECOG PS of 0,1, or 2~* MUGA scan or echocardiogram results show left ventricular ejection fraction greater than or equal to 50%~Exclusion Criteria:~* Radiation therapy within 2 weeks, chemotherapy within 3 weeks, or noncytoxic investigational agents within 4 weeks of initiating study treatment~* Evidence of New York Heart Association class III or greater cardiac disease~* History of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality~* History of congenital QT prolongation~* Concurrent severe or uncontrolled medical disease~* Symptomatic central nervous system metastases~* Pregnant or nursing women~* Hypersensitivity or intolerance to apricoxib, lapatinib, capecitabine, 5-FU, sulfonamides, aspirin, or NSAIDs~* Severe renal insufficiency~* History of upper GI bleeding, ulceration, or perforation- Concurrent use of potent CYP3A4 inhibitors and CYP3A4 inducers~* Prior treatment with capecitabine~* Patients on anti-arrhythmic treatment~* Prior lapatinib therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): apricoxib + lapatinib + capecitabine
- B (Type: PLACEBO_COMPARATOR): placebo + lapatinib + capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).